Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 627,200 shares, a decrease of 8.9% from the September 15th total of 688,800 shares. Currently, 2.1% of the company's shares are short sold. Based on an average daily trading volume, of 96,300 shares, the days-to-cover ratio is presently 6.5 days.
Anixa Biosciences Price Performance
NASDAQ ANIX traded down $0.02 during mid-day trading on Tuesday, hitting $3.03. The company's stock had a trading volume of 67,606 shares, compared to its average volume of 108,740. The firm has a market capitalization of $96.98 million, a P/E ratio of -8.19 and a beta of 0.86. Anixa Biosciences has a 52-week low of $2.14 and a 52-week high of $5.13. The stock's fifty day simple moving average is $3.21 and its two-hundred day simple moving average is $2.96.
Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Friday, September 6th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, equities analysts forecast that Anixa Biosciences will post -0.42 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on ANIX shares. EF Hutton Acquisition Co. I upgraded Anixa Biosciences to a "strong-buy" rating in a report on Wednesday, August 7th. HC Wainwright restated a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a research note on Tuesday, September 17th.
Get Our Latest Stock Analysis on Anixa Biosciences
Insider Buying and Selling
In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. purchased 21,646 shares of the stock in a transaction on Tuesday, July 30th. The stock was bought at an average price of $3.06 per share, for a total transaction of $66,236.76. Following the acquisition, the director now directly owns 890,754 shares of the company's stock, valued at $2,725,707.24. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. 22.60% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Anixa Biosciences
A number of large investors have recently modified their holdings of the stock. Staley Capital Advisers Inc. acquired a new stake in Anixa Biosciences during the 1st quarter valued at $31,000. Concorde Asset Management LLC acquired a new stake in shares of Anixa Biosciences during the second quarter valued at about $31,000. Virtu Financial LLC grew its stake in shares of Anixa Biosciences by 47.2% during the first quarter. Virtu Financial LLC now owns 16,156 shares of the company's stock valued at $50,000 after acquiring an additional 5,183 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its position in shares of Anixa Biosciences by 50.0% during the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company's stock worth $50,000 after acquiring an additional 7,500 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company's stock.
About Anixa Biosciences
(
Get Free Report)
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Featured Articles
Before you consider Anixa Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anixa Biosciences wasn't on the list.
While Anixa Biosciences currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.